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ABSTRACT Lipid A aminoarabinosylation is invariably associated with colistin
resistance in Pseudomonas aeruginosa; however, the existence of alternative
aminoarabinosylation-independent colistin resistance mechanisms in this bacterium
has remained elusive. By combining reverse genetics with experimental evolution as-
says, we demonstrate that a functional lipid A aminoarabinosylation pathway is criti-
cal for the acquisition of colistin resistance in reference and clinical P. aeruginosa iso-
lates. This highlights lipid A aminoarabinosylation as a promising target for the
design of colistin adjuvants against P. aeruginosa.
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The reintroduction of colistin in clinical practice as a last-resort treatment option forlife-threatening multidrug-resistant Gram-negative infections has inevitably led to
the spread of colistin-resistant isolates (1). Gram-negative bacteria acquire colistin
resistance primarily through remodeling the lipid A moiety of lipopolysaccharide (LPS)
by the covalent addition of 4-amino-4-deoxy-L-arabinose (L-Ara4N) and/or phospho-
ethanolamine (PEtN), which reduces LPS affinity for colistin. However, other polymyxin
resistance mechanisms have been described, such as lipid A glycosylation or acylation,
capsule formation, and overexpression of efflux pumps and/or basic outer membrane
proteins, which can bind and mask the divalent cation-binding sites of LPS (2, 3).
Adaptive resistance to colistin in Pseudomonas aeruginosa clinical isolates is always
associated with overexpression of the arn operon, encoding the enzymes for L-Ara4N
addition to lipid A (4–6). In this bacterium, arn expression is controlled by a complex
regulatory network involving at least five two-component systems (TCSs) (7–11). Ac-
cordingly, mutations within these TCSs resulting in constitutive activation of the arn
operon are typically identified in colistin-resistant P. aeruginosa strains (6, 12, 13). A
recent experimental evolution and comparative genomics study proposed that the
evolution of high levels of colistin resistance in P. aeruginosa invariably involves
mutations in crucial nodes, including two TCSs controlling arn expression and the
outer membrane protein Opr86 (BamA), followed by mutations in genes unrelated to
L-Ara4N accounting for high resistance levels (14). However, a previous study provided
evidence that individual TCSs are not essential for the acquisition of colistin resistance
in P. aeruginosa, leading to the hypothesis that alternative or compensatory mecha-
nisms may exist (12). This is in line with the results of independent random transposon
mutagenesis analyses or genome sequencing of colistin-resistant clinical isolates which
identified some genes unrelated to L-Ara4N likely involved in polymyxin resistance in P.
aeruginosa (11, 15, 16).
To definitely clarify the relevance of lipid A aminoarabinosylation to the acquisition
of colistin resistance in P. aeruginosa, as well as the existence of possible alternative
colistin resistance mechanisms, we generated a mutant impaired in the first committed
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steps of L-Ara4N biosynthesis in the reference strain PAO1 (PAO1 ΔarnBCA), as de-
scribed in the supplemental material. This mutant showed the same colistin MIC of its
parental strain (Table 1), implying that the arn operon does not affect the basal level of
colistin resistance, at least in our experimental setting.
To verify the effect of arn deletion on acquired colistin resistance, we first deter-
mined the frequency of colistin-resistant spontaneous mutants by plating on Mueller-
Hinton agar plates containing 5 or 10 g/ml colistin. The frequency of resistance was
3.3  107 and 1.4  107 for the parental strain PAO1 in the presence of 5 and 10
g/ml colistin, respectively, while it was 55- and 190-fold lower for PAO1 ΔarnBCA
(6.1  109 and 7.4  1010 with 5 and 10 g/ml colistin, respectively). As a control,
no differences were observed in the frequency of spontaneous mutants resistant to an
antibiotic with a different mechanism of action (gentamicin; data not shown). In 13
independent experiments, only 16 and 4 colonies were obtained for the PAO1 ΔarnBCA
mutant on plates with 5 and 10 g/ml colistin, respectively. To confirm the colistin-
resistant phenotype, the colistin MICs for these mutants were determined and com-
pared to those of spontaneous mutants from the wild-type PAO1. Surprisingly, we
found that 85% of spontaneous mutants of PAO1 ΔarnBCA had the same MIC as the
parental strain (0.5 g/ml), and only 2 isolates showed a slight (2-fold) increase in
colistin MIC (1 g/ml; see Fig. S1 in the supplemental material), indicating that all the
spontaneous mutants obtained on plates for PAO1 ΔarnBCA were false positives. In
contrast, colistin resistance in spontaneous mutants of the wild-type PAO1 was much
more varied, with 65% of isolates showing an MIC 4- to 16-fold higher than that of
the parental strain (Fig. S1), although none of the spontaneous mutants had a colistin
MIC higher than the maximum colistin concentration present on agar plates (10 g/ml).
While the above-described results suggest that the L-Ara4N-deficient mutant is
much less prone to develop colistin resistance by spontaneous mutation(s), the selec-
tion of spontaneous mutants on colistin-containing agar plates did not allow us to
obtain highly resistant isolates. We therefore sequentially cultured PAO1 and PAO1
ΔarnBCA in the presence of increasing concentrations of colistin (from 0.25 to 16 g/ml,
corresponding to 0.5 to 32 the MIC) in the attempt to select for mutants which
acquire successive mutations leading to high-level colistin resistance (see the supple-
mental material for experimental details). In 15 independent assays, the PAO1 ΔarnBCA
mutant never grew with colistin concentrations higher than 2 g/ml, while the wild-
type PAO1 always acquired the ability to grow in the presence of 16 g/ml colistin (Fig.
1A). The reintroduction of arnBCA in trans restored the ability of PAO1 ΔarnBCA to
develop colistin resistance (Fig. S2). MIC assays on a representative number of isolated
colonies from cultures with the highest colistin concentration that allowed growth
confirmed that the PAO1 ΔarnBCA mutant did not acquire high levels of resistance
(colistin MIC, 2 g/ml), while colistin MICs for PAO1 derivatives ranged between 32
and 128 g/ml.
To rule out that the relevance of the arn operon for acquired colistin resistance is
strain dependent, ΔarnBCA mutants were generated in different backgrounds, i.e., the
reference clinical strain PA14, which was isolated from a burn patient and that is
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distantly related to PAO1 (17), and 3 cystic fibrosis isolates (KK1, KK27, and TR1; Table
S1). As for PAO1, the colistin MIC for these ΔarnBCAmutants was comparable to or only
2-fold lower than that of the parental strains (Table 1), confirming that the arn operon
marginally contributes to basal levels of colistin resistance. Conversely, the arn operon
was found to be critical for acquired resistance to colistin also in these isolates, as all
ΔarnBCA mutants failed to develop resistance to 2 g/ml colistin in 15 independent
experimentally induced resistance assays. Their parental isolates readily acquired high-
level resistance to colistin, with the exception of a single culture of the KK1 strain (Fig.
1A). The acquired colistin-resistant phenotype was stable, as the colistin MIC was not
significantly reduced after several passages in colistin-free medium (Table S2). Notably,
colistin MIC was strongly reduced upon deletion of the arnBCA genes in in vitro-evolved
colistin-resistant PAO1 or PA14 isolates (Table S3), in line with the results from previous
reports (5).
Taking into consideration the number of replicates and the level of colistin resis-
tance reached by each replicate, the above-described assay involved relatively few
generations for the ΔarnBCAmutants, ranging from 385 to 450 generations per mutant.
To assess whether colistin resistance could be selected for in a higher number of
generations, a long-term experiment was performed for the ΔarnBCA mutants by
subculturing 15 independent cultures for each mutant for 5 serial passages in the
presence of each increasing concentration of colistin (see supplemental material for
experimental details). While prolonged exposure to increasing colistin concentrations
stabilized the acquisition of a low-level resistance phenotype by ΔarnBCA mutants (up
to 2 g/ml colistin), none of the cultures were able to grow in the presence of 2
g/ml colistin (Fig. 1B). This indicates that in our experimental setting, high levels of
colistin resistance were not developed in the absence of a functional arn operon even
after 2,000 generations per mutant (ca. 140 generations per independent culture).
Recently, lipid A aminoarabinosylation and the development of colistin resistance were
observed in arnB-deleted P. aeruginosa (18), suggesting that the L-Ara4N biosynthesis
pathway can somehow remedy the lack of ArnB in P. aeruginosa. Our study shows that
this does not occur in ArnBCA-deficient cells.
In conclusion, this work demonstrates that a functional arn operon and, thus,
aminoarabinosylation of lipid A are required for acquired colistin resistance in both
reference and clinical isolates of P. aeruginosa. Indeed, none of the ΔarnBCA mutants
became resistant to4 g/ml colistin, which corresponds to the epidemiological cutoff
(ECOFF) of colistin for P. aeruginosa (http://www.eucast.org/fileadmin/src/media/PDFs/
EUCAST_files/Rationale_documents/Colistin_rationale_1.0.pdf), i.e., the highest MIC for
isolates devoid of any detectable acquired resistance mechanisms (19). Thus, our data
directly confirm that lipid A aminoarabinosylation is a critical prerequisite for the
acquisition of colistin resistance in this pathogen (5, 6, 9, 14). This evidence, together
FIG 1 Maximum colistin resistance acquired by reference (PAO1 and PA14) or cystic fibrosis P. aeruginosa isolates (KK1, KK27, and TR1)
and/or their corresponding ΔarnBCA mutants after sequential passages in Mueller-Hinton broth in the presence of increasing colistin
concentrations (0.25 to 16 g/ml) in a short-term experiment (single passage at each colistin concentration) (A) or a long-term
experiment (5 serial passages at each colistin concentration) (B) (see supplemental material for experimental details). Fifteen
independent cultures were analyzed for each strain in each experiment. Cultures showing no visible growth after 5 days were
considered extinct.
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with recent observations that the addition of PEtN to lipid A, by either endogenous
(EptA) or plasmid-harbored PEtN transferases (MCR-1), has marginal effects on colistin
resistance in P. aeruginosa (20, 21), implies that pharmacological inhibition of L-Ara4N
biosynthetic enzymes could represent a suitable approach to extend the anti-
Pseudomonas clinical lifetime of colistin.
SUPPLEMENTAL MATERIAL
Supplemental material for this article may be found at https://doi.org/10.1128/AAC
.01820-17.
SUPPLEMENTAL FILE 1, PDF file, 0.6 MB.
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